Skip to content
DataLookout
Menu

NCT07905950

Exploratory Study of Short-Course Radiotherapy Followed by Adebrelimab Combined With Chemotherapy for Organ Preservation in Locally Advanced Rectal Cancer

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

the complete response (CR) rate assessed at the end of Cycle 4 or Cycle 8
Timeframe: at the end of Cycle 4 or Cycle 8(each cycle is 21 days).

Secondary (9)

The 3-year event-free survival (EFS) rate
3-year overall survival (OS) rate
The median event-free survival (mEFS)
The median overall survival (mOS)
The local recurrence rate (LRR)
Show 4 moreShow less
R0 resection rate
distant metastasis rate (DM)
The organ preservation rate
incidence of adverse events (AEs)

Arms and interventions

treatment armExperimental

Drugs: Adebrelimab

Sites

1 site in 1 country

  • Henan Cancer HospitalZhengzhou, Henan, China